NASDAQ •
Healthcare •
Biotechnology •
Quote as of 05/15/2026
Company Profile
IndustryBiotechnology
SectorHealthcare
ExchangeNASDAQ
Market Capitalization81.16 mln
Float21.35 mln
Earnings Date05/15/2026
Piotroski F-Score
2
/ 9
Weak
Relative Strength
75
/ 100
Strongly outperforming
Debt / Equity
0.00
Debt-free
ROE
-140
Deeply negative
Dividend Yield
0.00%
No dividend
DPS
0.00
No dividend
Business Description
Rein Therapeutics is a US-based drug development company working on treatments for rare lung and fibrosis diseases that currently have few or no effective options. Its most advanced programs include LTI-03, a peptide being tested in clinical trials for idiopathic pulmonary fibrosis, and LTI-01, which has already completed early-stage trials for a serious fluid buildup condition affecting the lungs. The company also has several earlier-stage programs targeting cystic fibrosis and broader fibrosis conditions. Founded in 2001 and based in Austin, Texas, Rein Therapeutics was previously known as Aileron Therapeutics before adopting its current name in 2007.
